Galimedix, Inc.
March 08, 2024
Galimedix, Inc.
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
View Article
February 28, 2024
Galimedix, Inc.
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference
View Article
October 25, 2023
Galimedix, Inc.
Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations (news with additional features)
View Article